Camille Farnos

Dr. Camille Farnos


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
CFCamille Farnos
Camille Farnos
VBVincent Barbier
Vincent Barbier
MDMarie Doussière
Marie Doussière
VDValentine Deprez
Valentine Deprez
YHYannis Hamidou
Yannis Hamidou
Vincent GoebVincent Goeb
Vincent Goeb
Background/Objectives: Janus kinase inhibitors (JAKis) belong to a new class of targeted oral drugs that have been added to the therapeutic arsenal for rheumatoid arthritis (RA). The aim of this study was to evaluate the efficacy and safety profiles of these four available molecules (tofacitinib, baricitinib, filgotinib, and upadacitinib) in real life. Methods: A retrospective, single-center observational study including all patients treated with JAKis for RA from 1 October 2017 to 1 December 2023. We assessed the maintenance rate at 24 months, which is an indirect reflection of the clinical and biological safety and efficacy profiles. Results: The 76 patients in our study were thus treated for the first time with anti-JAK, including 55 patients with baricitinib (BAR), 9 patients with tofacitinib (TOF), 4 patients with upadacitinib (UPA), and 8 patients with filgotinib (FIL). The majority of our patients had BAR introduced as the first intention. The therapeutic maintenance at 2 years for all our patients was 50%. The average maintenance duration was 8.6 months and was similar in all the groups. Of the 76 patients included in this study treated with Baricitinib (72.3%), 38 (50%) discontinued their treatment after two years of follow-up. Conclusions: Although this retrospective study is subject to various biases, it shows that the persistence rates of the four JAKi molecules in daily practice did not differ significantly, thus confirming the long-term efficacy of these drugs.

15 March 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
YHYannis Hamidou
Yannis Hamidou
JDJean-Marc Sobhy Danial
Jean-Marc Sobhy Danial
TBThibault Balcaen
Thibault Balcaen
Sophie LiabeufSophie Liabeuf
Sophie Liabeuf
SLSolene M Laville
Solene M Laville
Vincent GoebVincent Goeb
Vincent Goeb
Background/Objectives: Inflammatory pathologies are at the center of various medical specialties and benefit from conventional treatments as well as biological treatments. These latter ones have often been the subject of studies yielding heterogeneous results regarding their infectious and mortality risks. This work aims to describe mortality and its causes in patients afflicted by inflammatory pathologies, receiving either conventional or biological therapy during their first stay in intensive care units. Methods: Our study was conducted using the French national health database, encompassing all hospital stays on a national scale. All comparisons between conventional treatment and biological therapies were performed using the Chi-square test, Fisher’s exact test, or Student’s t-test. Results: In total, 13,816 patients were included. Within 90 days of the first admission to the intensive care/reanimation service, 11.6% of the patients died, including 9.4% within 30 days and 7.3% during hospitalization. More patients died in the conventional treatment group in comparison to the biological treatment group. More deaths were observed due to cardiovascular (27%), infectious (15%), gastroenterological (12%), and oncological (12%) conditions in the conventional treatment group. However, there were as many deaths from oncological causes (19%) as from cardiovascular causes (19%) in the biological therapy group. Hypertension (66.8%) and renal insufficiency (50.4%) were the most frequently associated comorbidities with mortality. Conclusions: Mortality in intensive care/reanimation during the initial stay of patients afflicted by inflammatory pathologies is of greater concern for those treated with conventional treatments. Causes of death tend to be more cardiovascular and require more prevention and care management.